

UF BPA Appendix for the MAY 2014 DoD P&T Meeting
 Uniform Formulary Price Quotes and
 Uniform Formulary Blanket Purchase Agreements (BPA)

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF BPA price quotes are to be submitted by the Company.

The Company must submit a separate, complete UF BPA price quote for each NDC that applies to the Company's pharmaceutical agent(s) in a given drug class.

Medications placed on the Uniform Formulary but not BCF or ECF are available for the local Military Treatment Facility P&T to decide whether to place on their individual formulary.

Grandfathering: a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process.

No grandfathering: a prior authorization process, would require all patients, regardless of past medication history to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user.

Grandfathering unstipulated: TMA reserves the right to choose the grandfathering or no-grandfathering of some or all agents based the total price/clinical evaluations after quotes have been submitted and in the best interests of the Government.

NDC	Drug Name	Strength	Dosage Form	Package Size	Unit of Measure

PEC Class: OSTEOPOROSIS AGENTS PEC SubClass: BISPHOSPHONATES				
Class Note(s): Prior Authorization may apply.				
Step Therapy Addendum: Cost effective generics may be before step therapy. Grandfathering unstipulated.				
Condition Set #	Category **	One of (X) Number of brand agents	Military Treatment Facility & Mail Order	
			Price per Unit of Measure (each, gram, mil) to 4 decimal places	Price Per NDC to 4 decimal places
Military Treatment Facility: 201403OSBI1UFBS1X Mail Order: 201403OSBI1T2BS1X	Uniform Formulary & Tier 2 After Step Therapy	1		